 Dapagliflozin is a selective and reversible inhibitor of the sodium-glucose co-transporter type 2 SGLT-2, which reduces renal reabsorption of glucose and promotes the excretion of glucose through the urine, in the way that glucose blood. Another reported effects is the decrease on BP, so it would be interesting to evaluate this effects in patients with prediabetes and prehypertension, as a potential therapy to treat disorders and to prevent progression to DM2 and HT, respectively. 